Neurocrine Biosciences reported a 41% year-over-year revenue increase to $1.1 billion in Q3 2026, driven by strong sales of INGREZZA, CRENESSITY, and VYKAT XR. INGREZZA sales grew 17% to $801 million, prompting an upward revision of full-year 2026 guidance to $2.9-$2.925 billion. The company also advanced its clinical pipeline with new Phase 1 and Phase 2 trials and announced leadership changes. Looking ahead, Neurocrine expects continued growth and key clinical milestones in 2027, including Phase 3 results for treatments targeting major depressive disorder and schizophrenia.
Neurocrine Biosciences (NBIX) shares are trading at USD 160.00 on Pluang as of Nov 03, 2026 05:02 WIB, which is closer to its 52-week high of USD 185.50 than its low of USD 123.10. Despite a strong 9.51% gain in one day, all recent Pluang order activity is selling. This contrasts with the company’s reported robust revenue growth and upward guidance, highlighting a cautious market stance.
